{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:11Z","timestamp":1792047131322,"version":"4.4.0"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: The necessity for ground-breaking treatments for Gram-negative infections is evident. The World Health Organization, the Infectious Diseases Society of America, and the European Commission have highlighted the critical insufficiency of efficient antibiotics, urging pharmaceutical businesses to manufacture new antibiotics. Therefore, developing new antibiotics with broad efficacy against Gram-negative pathogens is essential. Thus, this research aimed to evaluate the safety and effectiveness of cefiderocol in treating multidrug-resistant Gram-negative bacterial infections at the International Medical Center (IMC), Jeddah, Saudi Arabia. Methods: A retrospective analysis was conducted on patients treated from January 2021 to February 2023. Thirteen case groups treated with cefiderocol were compared to twenty control groups treated with other antibiotics. Results: The results indicated no statistically significant differences in ICU stay, comorbidity indices, or mortality rates between the two groups. Cefiderocol showed high clinical and microbiological cure rates, despite the severity of the patients\u2019 conditions. Carbapenem-resistant Klebsiella pneumoniae and difficult-to-treat resistance Pseudomonas aeruginosa were the most prevalent pathogens in the case and control group, respectively. Two patients treated with cefiderocol developed Clostridioides difficile infection, emphasizing the need for close monitoring of potential adverse effects. Conclusions: The results of this study support cefiderocol as a viable alternative for managing serious infections instigated by multidrug-resistant Gram-negative bacteria.<\/jats:p>","DOI":"10.3390\/antibiotics13111043","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:52:54Z","timestamp":1730713974000},"page":"1043","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Use of Cefiderocol in Gram-Negative Bacterial Infections at International Medical Center, Jeddah, Saudi Arabia"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-8726","authenticated-orcid":false,"given":"Reham","family":"Kaki","sequence":"first","affiliation":[{"name":"Department of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"},{"name":"Department of Medicine, International Medical Center, Jeddah 21589, Saudi Arabia"},{"name":"Department of Infectious Disease, King Abdulaziz University, Jeddah 21589, Saudi Arabia"},{"name":"Department of Infectious Disease, International Medical Center, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0332-4970","authenticated-orcid":false,"given":"Amjad","family":"Taj","sequence":"additional","affiliation":[{"name":"Department of Medicine, International Medical Center, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Bagaaifar","sequence":"additional","affiliation":[{"name":"Department of Medicine, International Medical Center, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: A review in serious Gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562872211065570","article-title":"Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract","volume":"14","author":"Wang","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26723","DOI":"10.1074\/jbc.270.45.26723","article-title":"Siderophores: Structure and function of microbial iron transport compounds","volume":"270","author":"Neilands","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"V23","DOI":"10.1093\/jac\/dkab352","article-title":"Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections","volume":"76","author":"Bassetti","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/phar.2476","article-title":"Cefiderocol: A novel Siderophore cephalosporin against multidrug-resistant gram-negative pathogens","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4167\/jbv.2020.50.4.218","article-title":"A novel antibiotic agent, cefiderocol, for multidrug-resistant Gram-negative bacteria","volume":"50","author":"Rahman","year":"2020","journal-title":"JBV"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jinf.2012.10.028","article-title":"Predictors of mortality in patients with infections due to multi-drug resistant Gram-negative bacteria: The study, the patient, the bug or the drug?","volume":"66","author":"Vardakas","year":"2013","journal-title":"J. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America antimicrobial resistant treatment guidance: Gram-negative bacterial infections","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","unstructured":"World Health Organization (2021, May 11). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: https:\/\/www.who.int."},{"key":"ref_14","unstructured":"Centers for Disease Control and Prevention (2021, May 11). Antibiotic Resistance Threats in the United States, Available online: https:\/\/www.cdc.gov."},{"key":"ref_15","unstructured":"(2023, March 05). International Medical Center. Available online: https:\/\/www.imc.med.sa\/ar."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomized, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomized, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of Cefiderocol, a novel siderophore Cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","article-title":"In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii","volume":"41","author":"Ni","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/cid\/ciad526","article-title":"Executive summary: State-of-the-art review: State of the management of infections caused by multidrug-resistant Gram-negative organisms","volume":"77","author":"Yassin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, N., Jia, H., Zhou, B., Zhou, C., Cao, J., Liao, W., and Ye, J. (2022). Hypervirulent carbapenem-resistant Klebsiella pneumoniae causing highly fatal meningitis in southeastern China. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.991306"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/mdr.2014.0121","article-title":"Molecular characterization of carbapenemase production among Gram-negative bacteria in Saudi Arabia","volume":"21","author":"Memish","year":"2015","journal-title":"Microb. Drug Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.02050-13","article-title":"Molecular characterization of carbapenemase-producing E. coli and K. pneumoniae in the countries of the Gulf cooperation council: Dominance of OXA-48 and NDM producers","volume":"58","author":"Zowawi","year":"2014","journal-title":"AAC"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","article-title":"Cefiderocol use in Gram-negative infections with limited therapeutic options: Is combination therapy the key?","volume":"15","author":"Corcione","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00194-23","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug-and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofad413","DOI":"10.1093\/ofid\/ofad413","article-title":"Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: A case-control study","volume":"10","author":"Miller","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: A meta-analysis","volume":"68","author":"Deshpande","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sajib, M.I., Monteforte, M., and Go, R. (2023). Clinical outcome of cefiderocol for infections with carbapenem-resistant organisms. Antibiotics, 12.","DOI":"10.3390\/antibiotics12050936"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S095026889900432X","article-title":"Widespread environmental contamination with Norwalk-like viruses (NLV) detected in a prolonged hotel outbreak of gastroenteritis","volume":"125","author":"Cheesbrough","year":"2000","journal-title":"Epidemiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.26719\/2016.22.3.193","article-title":"Accuracy of the VITEK 2 system for a rapid and direct identification and susceptibility testing of gram-negative rods and gram-positive cocci in blood samples","volume":"22","author":"Nimer","year":"2016","journal-title":"East. Mediterr. Health J."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1043\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:28Z","timestamp":1760113708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["antibiotics13111043"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13111043","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}